Nicorette Transdermal Therapeutic System 25 mg / 16 h, translucent patch in sachet, # 7
Dosage:
1 cm 2 dose released by TTS in 16 hours, nicotine 830 μg 15 mg
10mg / 16h
15mg / 16h
Category
Smoking
Scope of the medicinal product
Metabolism
Release form
Patch
Manufacturer country
Germany
Package quantity, pcs
7
Nicorette Transdermal Therapeutic System 25mg / 16h translucent patch in sachet # 7
Name ENG
NICORETTE
Clinical and pharmacological group
Drug for the treatment of nicotine addiction
ATX code
Nicotine
Dosage
1 cm 2 dose released by TTS in 16 hours, nicotine 830 μg 15 mg
Structure
The composition of 1 transdermal patch includes:
Active substance: nicotine - 23.62 mg (dose released in 16 hours - 15 mg)
Auxiliary components (15 mg at 16 h): triglycerides (average chain length) - 27.41 mg, copolymer of basic butyl methacrylate - 21.87 mg, polyethylene terephthalate film 19 m (on one side can be varnished) - carrier of the layer containing the active substance
Acrylate base (15 mg at 16 h): acrylic adhesive solution - 185.76 mg, potassium hydroxide - 1.05 mg, croscarmellose sodium - 7.49 mg, aluminum acetylacetonate - 0.09 mg, polyethylene terephthalate film 100? M, siliconized on both sides and aluminized on one side - the removable backing (the carrier is the protection of the adhesive layer), discarded before use.
Indications
For the treatment of tobacco dependence by reducing the need for nicotine, relieving withdrawal symptoms that occur when smoking cessation in patients with appropriate motivation
Storage conditions and periods
The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C.
Contraindications
Hypersensitivity to nicotine or other components of the drug. With caution Patients with recent myocardial infarction, unstable angina pectoris or worsening of its course, including Prinzmetal's angina, with severe arrhythmia, recent cerebrovascular disease and / or patients with uncontrolled hypertension should be advised to stop smoking without the help of pharmacological intervention. If such attempts are unsuccessful, the use of the Nicorette® patch can be considered, however, since the safety data in this category of patients is limited, such treatment should be started only under strict medical supervision.Patients with diabetes mellitus after smoking cessation and since the beginning of nicotine replacement therapy are recommended to more closely monitor the blood glucose concentration, since a decrease in the content of catecholamines, the release of which is induced by nicotine, can affect the metabolism of carbohydrates. Patients with diabetes may need to lower their insulin dose after smoking cessation. The drug should be used with caution in patients with severe or moderate hepatic impairment and / or severe renal impairment, since the clearance of nicotine and its metabolites may be reduced, which may increase the risk of adverse events. Nicotine, both released from substitution therapy and absorbed during smoking, stimulates the release of catecholamines from the adrenal medulla.Therefore, the drug should be used with caution in patients with uncontrolled hyperthyroidism and pheochromocytoma. Nicotine can exacerbate the symptoms of esophagitis, gastritis or peptic ulcers, therefore, nicotine replacement therapy should be used with caution in this pathology.
INN / Active ingredient
Nicotine
Specifications
Category
Smoking
Scope of the medicinal product
Metabolism
Release form
Patch
Manufacturer country
Germany
Package quantity, pcs
7
Way of introduction
Outwardly
Vacation conditions
Without recipe
Brand name
Nicorette
The amount of the dosage form in the primary package
1 PC.
Primary packaging type
Sachet (sachet)
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Nicotine addiction treatment
Anatomical and therapeutic characteristics
N07BA01 Nicotine
Dosage form
Transdermal patch
Packaging
Box
Expiration date in days
1095
The target audience
Adult
Dosage (volume) of the substance in the preparation
nicotine - 39.37 mg
Package weight, g
35
Mode of application
:
Heavy smokers (from 20 cigarettes per day) are recommended to start therapy with the daily use of 1 patch 25 mg / 16 h for 2 months.
After that, the dose is reduced - 1 patch at 15 mg / 16 h for 2 weeks, then at 10 mg / 16 h during the same period.
For non-smokers (10 to 20 cigarettes per day), therapy is recommended to start with a 15 mg / 16 h patch for 2 months, then treatment is continued with a 10 mg / 16 h patch for 2 months.